Endocrine & Diabetes Pharmacology

Two non-insulin classes have transformed Type 2 Diabetes management by directly modifying cardiorenal disease progression. SGLT2 inhibitors (-flozins: empagliflozin, dapagliflozin, canagliflozin) block the sodium-glucose cotransporter-2 in the S1/S2 segments of the proximal convoluted tubule, lowering the renal threshold for glucose reabsorption and inducing glucosuria and natriuresis. Increased delivery of Na⁺ and Cl⁻ to the macula densa restores tubuloglomerular feedback, triggering adenosine-mediated constriction of the hyperfiltering afferent glomerular arteriole—which synergizes with ACEi/ARB efferent dilation to dramatically slow diabetic nephropathy progression while reducing HFrEF/HFpEF hospitalizations. Key board adverse effects include vulvovaginal candidiasis, UTIs, volume depletion, Fournier gangrene, and euglycemic diabetic ketoacidosis (serum glucose <250 mg/dL) due to decreased insulin-to-glucagon ratios. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and dual GIP/GLP-1 agonists (tirzepatide) stimulate glucose-dependent pancreatic β-cell insulin secretion, suppress α-cell glucagon release, delay gastric emptying, and act on hypothalamic satiety centers to drive 10–20% total body weight loss and major adverse cardiovascular event (MACE) reduction. They carry a boxed warning for medullary thyroid carcinoma (C-cell hyperplasia; contraindicated in MEN2A/2B) and risk of acute pancreatitis and gastroparesis.

Metformin (a biguanide) remains the first-line oral agent in newly diagnosed Type 2 Diabetes; it inhibits mitochondrial respiratory complex I and glycerophosphate dehydrogenase to activate hepatic AMP-activated protein kinase (AMPK), suppressing hepatic gluconeogenesis and enhancing peripheral GLUT4 insulin sensitivity while promoting mild weight loss without hypoglycemia. Because metformin is excreted unchanged by the kidneys, it accumulates in renal insufficiency and can precipitate fatal high-anion-gap lactic acidosis: metformin is strictly contraindicated when eGFR <30 mL/min/1.73 m² (avoid initiating if eGFR 30–45), must be held prior to iodinated IV contrast in patients with eGFR <60 or acute illness/hypoxia, and impairs ileal intrinsic factor-vitamin B₁₂ absorption during chronic therapy. Thiazolidinediones (pioglitazone, rosiglitazone) bind nuclear PPAR-γ transcription factors to upregulate adiponectin and GLUT4 expression; they improve non-alcoholic steatohepatitis (MASH) but increase ENaC-mediated renal sodium reabsorption—making them contraindicated in NYHA Class III/IV heart failure—and increase distal extremity fracture risk in postmenopausal women. Sulfonylureas (glipizide, glimepiride, glyburide) close ATP-sensitive K⁺ channels on pancreatic β-cells to trigger glucose-independent Ca²⁺ influx and insulin exocytosis, carrying high risks of weight gain and severe hypoglycemia (especially long-acting glyburide in older adults or CKD; severe sulfonylurea overdose is rescued with IV dextrose plus octreotide to suppress rebound endogenous insulin release).

In Type 1 Diabetes Mellitus and insulin-deficient Type 2 Diabetes, physiologic replacement mimics endogenous pancreatic beta-cell secretion using a basal-bolus regimen (total daily insulin dose ~0.4–0.6 units/kg/day): approximately 50% is administered as a peakless long-acting basal insulin (glargine, detemir, or degludec) to suppress overnight and fasting hepatic gluconeogenesis/glycogenolysis, and the remaining 50% is divided across three meals as rapid-acting prandial insulin (lispro, aspart, or glulisine) to cover postprandial carbohydrate excursions. When a patient on evening basal or NPH insulin presents with fasting morning hyperglycemia, clinicians must measure a 3:00 AM blood glucose (or inspect continuous glucose monitoring [CGM] overnight curves) to distinguish two opposing mechanisms: in the Dawn Phenomenon, nocturnal pulsatile surges of growth hormone and cortisol between 3:00 AM and 7:00 AM induce hepatic insulin resistance (3:00 AM glucose is normal or elevated → treated by increasing the evening basal insulin dose or shifting NPH to bedtime); in the Somogyi Effect, excessive evening insulin causes nocturnal hypoglycemia at 3:00 AM (<70 mg/dL, often with night sweats and nightmares), triggering a counter-regulatory surge of glucagon, epinephrine, cortisol, and growth hormone that produces rebound morning hyperglycemia (→ treated by decreasing the evening insulin dose).

Management of Diabetic Ketoacidosis (DKA—characterized by hyperglycemia >250 mg/dL, arterial pH <7.30, serum bicarbonate <18 mEq/L, high anion gap, and elevated serum/urine β-hydroxybutyrate) follows a rigid physiological sequence tested on every licensing exam. Even though total-body potassium stores are severely depleted (by 3–5 mEq/kg due to osmotic diuresis and secondary hyperaldosteronism), initial serum K⁺ often appears normal or elevated because insulin deficiency and acidemia shift K⁺ out of cells. Because intravenous Regular insulin stimulates sarcolemmal Na⁺/K⁺-ATPase and drives K⁺ rapidly back into the intracellular compartment, administering insulin to a hypokalemic patient will precipitate fatal ventricular arrhythmias. Therefore: (1) begin aggressive isotonic 0.9% normal saline resuscitation (1–1.5 L in the first hour); (2) check serum K⁺ BEFORE starting insulin—if serum K⁺ <3.3 mEq/L, HOLD insulin and infuse IV KCl (20–40 mEq/hr) until K⁺ ≥3.3 mEq/L; if serum K⁺ is 3.3–5.2 mEq/L, initiate IV Regular insulin (0.1 units/kg/hr) AND co-administer 20–30 mEq KCl per liter of IV fluids; if K⁺ >5.2 mEq/L, start insulin and recheck K⁺ every 2 hours; and (3) once serum glucose falls to 200–250 mg/dL, add D5W (5% dextrose) with 0.45% NaCl while continuing the IV insulin infusion until the anion gap closes (≤12 mEq/L) and ketoacidosis resolves, finally overlapping subcutaneous basal insulin by 2 hours before turning off the IV insulin pump.

Thionamides—propylthiouracil (PTU) and methimazole—inhibit thyroid peroxidase (TPO), blocking both oxidation/organification of iodide onto thyroglobulin tyrosyl residues and coupling of monoiodotyrosine (MIT) and diiodotyrosine (DIT), while PTU uniquely also inhibits peripheral 5'-deiodinase conversion of T₄ to active T₃. Because methimazole has a longer half-life (once-daily dosing) and avoids PTU's boxed warning for fulminant idiosyncratic hepatic necrosis, methimazole is first-line in non-pregnant patients. However, in pregnancy, methimazole crosses the placenta during first-trimester organogenesis to cause aplasia cutis congenita (scalp defects) and choanal/esophageal atresia; therefore, PTU is mandatory during the 1st trimester, followed by switching to methimazole in the 2nd and 3rd trimesters to protect maternal liver function. Both drugs carry a 0.3% risk of idiosyncratic agranulocytosis (ANC <500/mm³): any patient on PTU or methimazole presenting with acute fever or sore throat must immediately stop the drug and obtain a stat CBC with differential. In Thyroid Storm, drugs must be administered in strict sequence: (1) Propranolol (controls adrenergic storm and blocks 5'-deiodinase), (2) PTU (blocks new hormone synthesis and 5'-deiodinase), (3) Potassium Iodide (Lugol solution / SSKI) administered at least 1 hour AFTER PTU to induce the acute Wolff-Chaikoff effect without providing raw substrate for new hormone synthesis (the Jod-Basedow escape trap), and (4) Hydrocortisone or Dexamethasone (blocks T₄→T₃ conversion and treats relative adrenal insufficiency).

Adrenal steroid replacement and systemic anti-inflammatory therapy require matching glucocorticoid versus mineralocorticoid receptor affinities. Hydrocortisone (cortisol) and prednisone possess both glucocorticoid and mineralocorticoid activity, whereas dexamethasone and betamethasone are long-acting, pure glucocorticoids with zero mineralocorticoid activity (30× more potent than cortisol; used for cerebral edema, overnight dexamethasone suppression testing for Cushing syndrome, and fetal lung maturation via type II pneumocyte lecithin surfactant synthesis). Conversely, fludrocortisone is a potent mineralocorticoid essential alongside hydrocortisone in primary adrenal insufficiency (Addison disease and classic 21-hydroxylase congenital adrenal hyperplasia), where both zona fasciculata cortisol and zona glomerulosa aldosterone are lost (secondary pituitary ACTH deficiency spares RAAS-driven aldosterone and does not require fludrocortisone). Chronic glucocorticoid therapy accelerates bone loss by stimulating RANKL, suppressing osteoprotegerin, and inducing osteoblast apoptosis. First-line osteoporosis pharmacotherapy utilizes bisphosphonates (-dronates: alendronate, risedronate, zoledronic acid), which are pyrophosphate analogs incorporated into hydroxyapatite that inhibit farnesyl pyrophosphate synthase in osteoclasts to induce osteoclast apoptosis (requiring upright posture for 30 minutes with plain water to prevent corrosive pill esophagitis, and carrying rare risks of osteonecrosis of the jaw and atypical subtrochanteric femur fractures). Denosumab is a monoclonal antibody against RANKL (safe in severe CKD), while teriparatide (recombinant PTH 1-34 given as a once-daily subcutaneous pulse) and romosozumab (anti-sclerostin antibody) stimulate net osteoblastic bone formation.

Unlike all other pituitary adenomas (somatotroph, corticotroph, thyrotroph, and non-functioning gonadotroph macroadenomas), which are treated first-line with transsphenoidal surgical resection, lactotroph prolactinomas (both microadenomas <10 mm and macroadenomas ≥10 mm, even when compressing the optic chiasm to cause bitemporal hemianopsia) are treated FIRST-LINE medically with dopamine D₂ receptor agonists: cabergoline (preferred for higher efficacy and twice-weekly dosing) or bromocriptine. Because tuberoinfundibular hypothalamic dopamine tonically inhibits lactotroph gene transcription via G_i-coupled D₂ receptors, cabergoline rapidly normalizes serum prolactin, shrinks tumor volume by >50% within weeks, decompresses the optic chiasm, and restores pulsatile GnRH/LH/FSH ovulation and testosterone secretion. Conversely, in acromegaly (growth hormone-secreting somatotroph adenoma with elevated IGF-1), if transsphenoidal surgery fails to achieve remission, medical therapy utilizes octreotide or lanreotide (long-acting somatostatin analogs that bind somatotroph SSTR2/5 receptors to inhibit GH secretion, carrying an adverse effect of cholelithiasis and biliary sludging due to cholecystokinin inhibition) or pegvisomant (a competitive growth hormone receptor antagonist that blocks hepatic JAK2-STAT5 IGF-1 synthesis).

Arginine vasopressin (ADH) activates two distinct receptor subtypes: vascular smooth muscle V₁ receptors (G_q → IP₃/Ca²⁺ vasoconstriction) and renal collecting duct principal cell V₂ receptors (G_s → cAMP → PKA-mediated insertion of Aquaporin-2 water channels into the apical membrane), as well as endothelial V₂ receptors that trigger exocytosis of Weibel-Palade bodies containing von Willebrand factor (vWF) and Factor VIII. Desmopressin (DDAVP) is a selective V₂ receptor agonist with minimal V₁ vasoconstrictor activity; it is the drug of choice for central diabetes insipidus, primary nocturnal enuresis, mild Hemophilia A, Type 1 von Willebrand disease, and uremic platelet dysfunction. In contrast, nephrogenic diabetes insipidus (most commonly induced by lithium entering principal cells via ENaC and inhibiting GSK-3β/adenylyl cyclase, or by hypercalcemia/hypokalemia) is unresponsive to desmopressin and is treated with amiloride (for lithium-induced NDI, blocking ENaC lithium entry), thiazide diuretics (inducing mild volume contraction that enhances proximal tubular Na⁺ and water reabsorption), and NSAIDs (indomethacin) (blocking renal prostaglandin E₂, which normally antagonizes ADH). In SIADH, after fluid restriction and hypertonic 3% saline (for seizures), conivaptan (V_1A/V₂ antagonist) and tolvaptan (oral V₂ antagonist) promote free water excretion (aquaresis), always limiting serum Na⁺ correction to ≤8 mEq/L per 24 hours to prevent osmotic demyelination syndrome (central pontine myelinolysis).

Metformin inhibits mitochondrial Complex I of the respiratory chain in hepatocytes, elevating the intracellular AMP:ATP ratio to activate AMP-activated protein kinase (AMPK) and inhibit mitochondrial glycerophosphate dehydrogenase (mGPD). This suppresses hepatic gluconeogenesis, opposes glucagon signaling, and increases peripheral GLUT4-mediated insulin sensitivity without causing hypoglycemia or weight gain. Long-term metformin therapy impairs ileal intrinsic factor–Vitamin B₁₂ absorption, warranting periodic monitoring for macrocytic anemia and peripheral neuropathy.

SGLT2 Inhibitors (empagliflozin, dapagliflozin, canagliflozin) block the Sodium-Glucose Cotransporter-2 in the S1 segment of the proximal convoluted tubule (which normally reabsorbs 90% of filtered glucose). By inducing glucosuria and natriuresis, they restore tubuloglomerular feedback: increased Na⁺ delivery to the macula densa constricts the afferent arteriole via adenosine, reducing intraglomerular hyperfiltration pressure and slowing CKD progression while lowering heart failure hospitalization and cardiovascular death. Adverse effects include vulvovaginal candidiasis, UTIs, orthostatic hypotension, Fournier necrotizing perineal fasciitis, bone fractures (canagliflozin), and euglycemic DKA.

GLP-1 Receptor Agonists (semaglutide, liraglutide, dulaglutide, exenatide) and dual GLP-1/GIP agonists (tirzepatide) resist degradation by dipeptidyl peptidase-4 (DPP-4), potentiating glucose-dependent insulin secretion from pancreatic beta cells, suppressing alpha-cell glucagon release, delaying gastric emptying, and promoting hypothalamic satiety with substantial weight loss (10–20%) and ASCVD reduction. By contrast, oral DPP-4 inhibitors (sitagliptin, linagliptin, saxagliptin) block endogenous incretin degradation to confer weight-neutral, hypoglycemia-free modest A1c reduction (~0.5–0.8%); linagliptin is cleared via the biliary tract and is the only DPP-4 inhibitor requiring zero renal dose adjustment in CKD/ESRD (note: saxagliptin increases heart failure hospitalization risk).

Sulfonylureas (2nd generation: glipizide, glimepiride, glyburide; 1st generation: chlorpropamide, tolbutamide) and Meglitinides (repaglinide, nateglinide) bind the SUR1 subunit to close ATP-sensitive potassium (K_ATP) channels on pancreatic beta-cell membranes. Membrane depolarization opens voltage-gated Ca²⁺ channels, triggering preformed insulin exocytosis independently of blood glucose concentration. Consequently, their hallmark adverse effects are weight gain and severe, prolonged hypoglycemia (characterized by elevated insulin AND elevated C-peptide; glyburide has active renally cleared metabolites and is strictly avoided in older adults and CKD; chlorpropamide causes SIADH and disulfiram reactions).

Thiazolidinediones (pioglitazone, rosiglitazone) bind the nuclear transcription factor PPAR-γ in adipocytes and skeletal muscle, upregulating adiponectin and GLUT4 synthesis while reducing free fatty acid efflux. Because gene transcription requires weeks, clinical onset is delayed. TZDs improve non-alcoholic steatohepatitis (MASH/NASH) but cause weight gain, fluid retention/CHF exacerbation, osteoporotic fractures, and bladder cancer association (pioglitazone). Alpha-glucosidase inhibitors (acarbose, miglitol) competitively inhibit intestinal brush-border alpha-glucosidases, blunting postprandial hyperglycemia while causing osmotic flatulence and diarrhea (if hypoglycemia occurs on acarbose + insulin, treat with pure oral glucose/dextrose rather than sucrose table sugar, whose hydrolysis is blocked by acarbose).

Levothyroxine (synthetic T₄) is the treatment of choice for primary, secondary, and congenital hypothyroidism. Because T₄ is heavily bound (>99.9%) to Thyroxine-Binding Globulin (TBG) and has a 7-day plasma half-life, steady-state TSH takes 6 weeks to equilibrate. Pregnancy or exogenous oral estrogens stimulate hepatic TBG synthesis, expanding the total T₄ binding pool and requiring a 25–30% increase in levothyroxine dose to maintain normal free T₄. Conversely, liothyronine (synthetic T₃) has a rapid onset and short half-life, utilized alongside IV levothyroxine and stress-dose IV hydrocortisone (given FIRST to prevent precipitating acute adrenal crisis as metabolic clearance of cortisol accelerates!) in myxedema coma.

Methimazole and Propylthiouracil (PTU) inhibit thyroid peroxidase (TPO), blocking iodide oxidation, organification of tyrosine residues on thyroglobulin, and coupling of MIT/DIT. Crucially, ONLY PTU additionally inhibits peripheral 5'-deiodinase (blocking peripheral conversion of T₄ to active T₃), making PTU preferred in thyroid storm and during the first trimester of pregnancy. In thyroid storm, treatment follows a strict four-part physiological sequence: (1) Propranolol (controls beta₁ adrenergic tachyarrhythmias AND blocks peripheral 5'-deiodinase at high doses), (2) PTU (blocks new hormone synthesis and peripheral T₄→T₃ conversion), (3) Potassium Iodide (Lugol solution / SSKI) administered at least 1 hour after PTU to acutely inhibit proteolysis and release of preformed thyroid hormone (Wolff-Chaikoff effect), and (4) IV Hydrocortisone or Dexamethasone (inhibits peripheral T₄→T₃ conversion, treats vasopressor-refractory relative adrenal insufficiency, and suppresses Graves autoimmune TSI production).

Systemic corticosteroids vary across three clinical dimensions: anti-inflammatory (glucocorticoid) potency, mineralocorticoid (salt-retaining) potency, and biological half-life. Hydrocortisone (cortisol) possesses a 1:1 ratio of glucocorticoid to mineralocorticoid activity (short-acting, 8–12 hours). Prednisone and Methylprednisolone are intermediate-acting (12–36 hours) with 4–5× glucocorticoid potency and minimal mineralocorticoid activity. Dexamethasone and Betamethasone are long-acting (36–72 hours) with 25–30× glucocorticoid potency and ZERO mineralocorticoid activity—making dexamethasone ideal for cerebral edema, spinal cord compression, fetal lung maturation (betamethasone/dexamethasone cross the placenta because they resist placental 11β-HSD2 inactivation), and the overnight dexamethasone suppression test (because dexamethasone does not cross-react in serum/urine cortisol immunoassays). Conversely, Fludrocortisone exhibits massive mineralocorticoid potency (125–150× cortisol), required alongside hydrocortisone in primary adrenal insufficiency (Addison disease) and salt-wasting 21-hydroxylase deficiency (whereas secondary/tertiary pituitary adrenal insufficiency preserves RAAS-regulated aldosterone and requires glucocorticoid replacement ONLY).

Bisphosphonates (alendronate, risedronate, ibandronate, IV zoledronic acid, pamidronate) are pyrophosphate analogs that bind hydroxyapatite crystals in bone and are ingested by resorbing osteoclasts, where they inhibit farnesyl pyrophosphate synthase in the mevalonate pathway, inducing osteoclast apoptosis. First-line for postmenopausal and glucocorticoid-induced osteoporosis, Paget disease of bone, and malignant hypercalcemia, oral bisphosphonates cause severe corrosive esophagitis (patients must take with plain water on an empty stomach and remain upright for ≥30 minutes), transient hypocalcemia, medication-related osteonecrosis of the jaw (MRONJ) after dental extractions, and atypical subtrochanteric femoral shaft fractures with prolonged use (>5 years).

Denosumab is a humanized monoclonal antibody against RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand), mimicking endogenous osteoprotegerin (OPG) to block osteoclast differentiation and survival; unlike bisphosphonates, denosumab is not renally cleared and is safe in severe CKD (though correcting baseline hypocalcemia and Vitamin D deficiency beforehand is mandatory to prevent severe hypocalcemia). Teriparatide (recombinant PTH 1–34) and abaloparatide (PTHrP analog) are osteoblast-stimulating anabolic agents when administered as a once-daily subcutaneous bolus (whereas continuous PTH elevation, as in primary hyperparathyroidism, stimulates RANKL and net bone resorption). Teriparatide is avoided in patients with Paget disease, unexplained elevated alkaline phosphatase, prior skeletal radiation, or open epiphyses due to theoretical osteosarcoma risk in rodent studies. Romosozumab is a monoclonal antibody that inhibits sclerostin (an osteocyte-derived inhibitor of Wnt/beta-catenin signaling), uniquely exerting dual anabolic (increased bone formation) and antiresorptive effects (carries a boxed warning for myocardial infarction and stroke). Cinacalcet acts as an allosteric calcimimetic activator of the parathyroid Calcium-Sensing Receptor (CaSR), suppressing PTH in secondary hyperparathyroidism of ESRD and parathyroid carcinoma.

Dopamine D₂ Receptor Agonists (cabergoline > bromocriptine) mimic tuberoinfundibular dopamine to suppress lactotroph prolactin synthesis and shrink prolactinomas regardless of tumor size (even macroprolactinomas with chiasmal bitemporal hemianopsia are treated medically with cabergoline FIRST before considering transsphenoidal surgery!). For acromegaly (GH-secreting somatotroph adenoma), surgical resection is first-line, followed by somatostatin analogs (octreotide, lanreotide—inhibit GH and GI secretory hormones; cause cholelithiasis/steatorrhea) or the GH-receptor antagonist pegvisomant (blocks hepatic IGF-1 production). For posterior pituitary disorders, desmopressin (DDAVP) is a selective V₂-receptor agonist used for central diabetes insipidus, nocturnal enuresis, and mild Hemophilia A / Type 1 von Willebrand disease (stimulates endothelial Weibel-Palade body release of vWF and Factor VIII), whereas vaptans (tolvaptan, conivaptan) antagonize V₂ receptors to promote free-water aquaresis in hypervolemic/euvolemic hyponatremia (SIADH) and slow cyst growth in ADPKD.